242.74

0.80% 1.92

Insulet Corporation (PODD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PODD? Forum Prognose

Schlusskurs vom Vortag:

$240.82

Offen:

$241.63

24-Stunden-Volumen:

776.05K

Relative Volume:

0.95

Marktkapitalisierung:

$17.08B

Einnahmen:

$2.36B

Nettoeinkommen (Verlust:

$236.10M

KGV:

73.87

EPS:

3.286

Netto-Cashflow:

$382.50M

1W Leistung:

+0.33%

1M Leistung:

-12.74%

6M Leistung:

-21.36%

1J Leistung:

-13.96%

1-Tages-Spanne:

$241.63

$249.73

1-Wochen-Bereich:

$240.33

$255.71

52-Wochen-Spanne:

$230.05

$354.88

Insulet Corporation Stock (PODD) Company Profile

Firmenname

Insulet Corporation

Sektor

Healthcare (1111)

Branche

Medical Devices (139)

Telefon

978-600-7000

Adresse

100 NAGOG PARK, ACTON, MA

Mitarbeiter

3,900

Twitter

@insulet_uk

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PODD's Discussions on Twitter

Compare PODD vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PODD Insulet Corporation	242.74	16.94B	2.36B	236.10M	382.50M	3.286
ABT Abbott Laboratories	112.68	193.83B	44.33B	6.48B	6.92B	3.7033
SYK Stryker Corp	366.05	140.01B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	99.49	129.33B	34.76B	4.79B	5.21B	3.7017
BSX Boston Scientific Corp	74.73	109.92B	20.08B	2.89B	3.82B	1.9391
EW Edwards Lifesciences Corp	75.87	44.36B	6.07B	1.06B	799.60M	1.8527

Insulet Corporation Stock (PODD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-27	Fortgesetzt	TD Cowen	Hold
2026-01-12	Herabstufung	Barclays	Overweight → Equal Weight
2025-12-16	Eingeleitet	Evercore ISI	Outperform
2025-11-19	Hochstufung	UBS	Neutral → Buy
2025-10-21	Fortgesetzt	Stifel	Buy
2025-09-08	Fortgesetzt	Oppenheimer	Outperform
2025-06-16	Eingeleitet	Truist	Buy
2025-05-30	Eingeleitet	Goldman	Buy
2025-05-13	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-04-29	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-03-06	Eingeleitet	RBC Capital Mkts	Outperform
2024-11-06	Eingeleitet	Bernstein	Outperform
2024-05-30	Eingeleitet	Redburn Atlantic	Buy
2024-05-07	Hochstufung	Wolfe Research	Peer Perform → Outperform
2023-12-21	Hochstufung	Robert W. Baird	Neutral → Outperform
2023-12-04	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-10-02	Hochstufung	Jefferies	Hold → Buy
2023-08-21	Hochstufung	Citigroup	Neutral → Buy
2023-08-21	Herabstufung	Robert W. Baird	Outperform → Neutral
2023-05-30	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-01-26	Eingeleitet	Wolfe Research	Peer Perform
2022-11-04	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-18	Eingeleitet	Barclays	Equal Weight
2022-10-12	Eingeleitet	Jefferies	Hold
2022-07-11	Herabstufung	Citigroup	Buy → Neutral
2022-03-02	Fortgesetzt	BofA Securities	Buy
2022-02-03	Hochstufung	BTIG Research	Neutral → Buy
2022-02-02	Hochstufung	UBS	Neutral → Buy
2022-01-31	Hochstufung	Oppenheimer	Perform → Outperform
2021-07-21	Fortgesetzt	Cowen	Outperform
2021-05-25	Eingeleitet	Barclays	Overweight
2021-04-01	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2021-03-19	Hochstufung	Canaccord Genuity	Hold → Buy
2021-01-29	Herabstufung	Piper Sandler	Overweight → Neutral
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-07-28	Eingeleitet	Wells Fargo	Overweight
2020-04-24	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-04-03	Eingeleitet	BofA/Merrill	Neutral
2020-03-31	Herabstufung	Berenberg	Buy → Hold
2020-03-05	Eingeleitet	Citigroup	Buy
2019-12-10	Eingeleitet	CFRA	Sell
2019-10-23	Eingeleitet	Stifel	Hold
2019-10-18	Herabstufung	Canaccord Genuity	Buy → Hold
2019-10-14	Herabstufung	BTIG Research	Buy → Neutral
2019-10-04	Herabstufung	UBS	Buy → Neutral
2019-10-03	Herabstufung	Guggenheim	Buy → Neutral
2019-08-06	Hochstufung	JP Morgan	Neutral → Overweight
2019-06-10	Herabstufung	Northland Capital	Outperform → Market Perform
2019-05-06	Hochstufung	BTIG Research	Neutral → Buy
2018-04-20	Eingeleitet	Berenberg	Buy
2018-02-22	Bestätigt	Barclays	Overweight
2018-01-08	Hochstufung	Raymond James	Mkt Perform → Outperform
2017-11-03	Hochstufung	Canaccord Genuity	Hold → Buy
2017-09-15	Eingeleitet	Barclays	Overweight

Alle ansehen

Insulet Corporation Aktie (PODD) Neueste Nachrichten

Feb 13, 2026

Agree To Buy Insulet At $210, Earn 10.6% Annualized Using Options - Nasdaq

Feb 13, 2026

Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market - Benzinga

Feb 13, 2026

ING Groep NV Grows Stock Holdings in Insulet Corporation $PODD - MarketBeat

Feb 13, 2026

Feb 12, 2026

Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance

Feb 12, 2026

Impax Asset Management Group plc Invests $2.98 Million in Insulet Corporation $PODD - MarketBeat

Feb 12, 2026

Feb 11, 2026

Is Insulet Corporation’s growth already priced inWeekly Trade Report & Step-by-Step Trade Execution Guides - mfd.ru

Feb 11, 2026

Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth - Finviz

Feb 11, 2026

Candriam S.C.A. Sells 40,485 Shares of Insulet Corporation $PODD - MarketBeat

Feb 11, 2026

Insulet (PODD) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Feb 11, 2026

Feb 10, 2026

Is Insulet Corporation forming bullish engulfing patternsAnalyst Upgrade & AI Powered Market Trend Analysis - mfd.ru

Feb 10, 2026

Insulet launches Omnipod 5 and Omnipod Discover in the Middle East to transform diabetes care - ZAWYA

Feb 10, 2026

ZAWYA-PRESSR: Insulet launches Omnipod 5 and Omnipod Discover in the Middle East to transform diabetes care - TradingView

Feb 10, 2026

Feb 09, 2026

Is Insulet (NASDAQ:PODD) Using Too Much Debt? - 富途牛牛

Feb 09, 2026

Published on: 2026-02-09 20:06:25 - baoquankhu1.vn

Feb 09, 2026